Hepatic Cell News Volume 6.17 | Jul 8 2022

    By
    lbeveridge
    -
    0
    16







    08-07-2022 | HCN 6.24


    Hepatic Cell News by STEMCELL Technologies
    Vol. 6.1 – 8 July, 2022
    TOP STORY

    ORM 1 as a Biomarker of Increased Vascular Invasion and Decreased Sorafenib Sensitivity in Hepatocellular Carcinoma

    Researchers clarified the role of Orosomucoid 1 (ORM1) in the development and therapy resistance in HCC.
    [BJBMS]

    Abstract
    STEMCELL has implemented an Environmental Management System that is now ISO 14001-certified.
    PUBLICATIONSRanked by the impact factor of the journal

    Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency

    The authors investigated the safety and efficacy of fazirsiran, an RNA interference therapeutic, in patients with liver disease associated with alpha1-antitrypsin deficiency.
    [New England Journal of Medicine]

    Abstract

    Essential Lipid Autacoids Rewire Mitochondrial Energy Efficiency in Metabolic Dysfunction-Associated Fatty Liver Disease

    Researchers investigated whether changes in the content of essential fatty acid-derived lipid autacoids affected hepatocyte mitochondrial bioenergetics and metabolic efficiency.
    [Hepatology]

    Abstract

    Acetyl-CoA Metabolism Drives Epigenome Change and Contributes to Carcinogenesis Risk in Fatty Liver Disease

    Scientists demonstrated that metabolically driven histone hyperacetylation in steatotic hepatocytes could increase DNA damage to initiate carcinogenesis.
    [Genome Medicine]

    Full Article

    Replication Stress Triggered by Nucleotide Pool Imbalance Drives DNA Damage and cGAS-STING Pathway Activation in NAFLD

    The authors investigated the mechanisms underlying the activation of DNA damage response during non-alcoholic steatotic liver disease (NAFLD).
    [Developmental Cell]

    AbstractGraphical Abstract

    CRIP1 Suppresses BBOX1-Mediated Carnitine Metabolism to Promote Stemness in Hepatocellular Carcinoma

    Researchers reported that little characterized cysteine-rich protein 1 (CRIP1) was upregulated in HCC and associated with poor prognosis.
    [EMBO Journal]

    AbstractGraphical Abstract

    RNA Helicase DDX24 Stabilizes LAMB1 to Promote Hepatocellular Carcinoma Progression

    Scientists identified a novel role of DEAD-box helicase 24 (DDX24), a member of the DEAD-box protein family, in promoting HCC progression.
    [Cancer Research]

    Abstract

    A Vascularized Model of the Human Liver Mimics Regenerative Responses

    Investigators found that exposing the endothelium-lined channel to fluid flow led to increased secretion of regeneration-associated factors.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article
    ON1104SM-Small-Molecules-Wallchart-728x90
    REVIEWS

    Augmenter of Liver Regeneration: Mitochondrial Function and Steatohepatitis

    The authors review augmenter of liver regeneration, a ubiquitous fundamental life protein, and how it was expressed more abundantly in the liver than other organs.
    [Journal of Hepatology]

    Full Article

    In Vitro Models for Human Malaria: Targeting the Liver Stage

    The authors focused on the progression of in vitro liver models developed for human Plasmodium spp. parasites, provided a brief review on important assay requirements, and lastly presented recommendations to improve models to enhance the discovery process of novel preclinical therapeutics.
    [Trends in Parasitology]

    Full Article
    INDUSTRY AND POLICY NEWS

    Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®

    Alvotech announced the initiation of the company’s confirmatory clinical study for AVT06, a biosimilar candidate to Eylea®.
    [Alvotech]

    Press Release

    FDA Approves KRYSTEXXA® (Pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

    Horizon Therapeutics plc announced that the FDA has approved the supplemental Biologics License Application expanding the labeling to include KRYSTEXXA® injection co-administered with methotrexate, which will help more people with uncontrolled gout achieve a complete response to therapy.
    [Horizon Therapeutics plc]

    Press Release
    FEATURED EVENT

    EHA Research Conference 2022

    October 17 – October 20
    Palermo (Sicily), Italy

    > See All Events

    JOB OPPORTUNITIES

    Associate Professor – Thematic Research Programs

    The Chinese University of Hong Kong – Hong Kong, China

    Research Associate – Mechanochemistry

    University of Cambridge – Cambridge, England, United Kingdom

    Research Technologist – Pediatrics

    Pennsylvania State University – State College, Pennsylvania, United States

    Postdoctoral Associate – Cancer Biology and Metabolism

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Fellow – Computational Analysis of Human Microbiome Data

    European Molecular Biology Laboratory – Heidelberg, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hepatic Cell News Twitter